Showing 6 RESULTS FOR
Data
Harnessing the Power of AI to Speed Drug Discovery and Development
By Newsroom editorial staff
Lundbeck and a data-driven drug design company are collaborating to utilize AI to identify clinical candidates for brain disorder therapies.
New Study Used Personalized Goals to Assess Treatment Effectiveness for Patients with Major Depressive Disorder
Results from an open-label study evaluating the development and assessment of personalized goals as a way of measuring treatment effectiveness in MDD.
Data Demonstrate Safety and Efficacy of Brexpiprazole in Patients With Schizophrenia Experiencing Severe Psychotic Symptoms
Study on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. Severity of symptoms can be a significant predictor of poor treatment outcomes.
New Data Added to TRINTELLIX® (vortioxetine) Labeling Demonstrated Superiority Over Escitalopram in Improving SSRI-Induced Sexual Dysfunction in Patients with Major Depressive Disorder
TRINTELLIX® is the first antidepressant to include head-to-head data in its labeling that showed improvement in treatment-emergent sexual dysfunction in patients with MDD who switched from certain SSRI treatments.
Trintellix Prescribing Information Updated to Include New Data Showing Improvement in Processing Speed
Takeda Pharmaceutical Company Limited and H. Lundbeck A/S announced the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for TRINTELLIX® (vortioxetine). The FOCUS and CONNECT studies showed TRINTELLIX had a positive effect on processing speed, an important aspect of cognitive function that may be impaired in adult patients with acute MDD.